ELI LILLY & Co LLY

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $1,180.33
Market Cap $1.08T
P/E Ratio 51.43
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑44.7% YoY
$65.18B
3-Yr CAGR: 31.7%
Net Income ↑94.9% YoY
$20.64B
Net Margin: 31.7%
Free Cash Flow ↑138.6% YoY
$8.97B
FCF Yield: 0.83%
EPS (Diluted) ↑96.0% YoY
$22.95
Basic: $23.00
Return on Equity Efficiency
77.8%
ROA: 18.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (LLY)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $21,222.1M $15,567.2M $2,737.6M $2.58 $4,851.0M $3,814.0M
FY 2017 $22,871.3M +7.8% $16,801.1M $-204.1M -107.5% $-0.19 -107.4% $5,615.6M $4,538.8M +19.0%
FY 2018 $21,493.3M -6.0% $15,063.3M $3,232.0M +1,683.5% $3.13 +1,747.4% $5,524.5M $4,313.9M -5.0%
FY 2019 $22,319.5M +3.8% $17,598.3M $8,318.4M +157.4% $8.89 +184.0% $4,836.6M $3,802.7M -11.9%
FY 2020 $24,539.8M +9.9% $19,056.5M $6,193.7M -25.5% $6.79 -23.6% $6,499.6M $5,111.7M +34.4%
FY 2021 $28,318.4M +15.4% $21,005.6M $5,581.7M -9.9% $6.12 -9.9% $7,260.7M $5,950.9M +16.4%
FY 2022 $28,541.4M +0.8% $21,911.6M $6,244.8M +11.9% $6.90 +12.7% $7,084.4M $5,230.1M -12.1%
FY 2023 $34,124.1M +19.6% $27,041.9M $5,240.4M -16.1% $5.80 -15.9% $4,240.1M $792.5M -84.8%
FY 2024 $45,042.7M +32.0% $36,624.4M $10,590.0M +102.1% $11.71 +101.9% $8,817.9M $3,760.1M +374.5%
FY 2025 $65,179.0M +44.7% $54,127.0M $20,640.0M +94.9% $22.95 +96.0% $16,813.0M $8,972.0M +138.6%
$

Valuation

Market Price $1,180.33
Market Cap $1.08T
Enterprise Value $1.11T
P/E Ratio 51.43
P/B Ratio 39.67
FCF Yield 0.83%
Dividend Yield 0.53%
Shares Outstanding 891,741,400
%

Profitability & Margins

Gross Margin 83.04%
Operating Margin 42.10%
Net Margin 31.67%
Return on Equity (ROE) 77.78%
Return on Assets (ROA) 18.35%
Asset Turnover 0.58x
Revenue 3-Yr CAGR 31.69%
🛡️

Financial Health & Liquidity

Current Ratio 1.58
Cash Ratio 0.21
Debt / Equity 1.602
Debt / Assets 0.378
Cash & Equivalents $7.27B
Total Debt $42.50B
Book Value / Share $29.76
💧

Cash Flow Efficiency

Operating Cash Flow $16.81B
Capital Expenditures (CapEx) $7.84B
Free Cash Flow $8.97B
OCF / Revenue 25.80%
FCF / Revenue 13.77%
FCF 3-Yr CAGR 19.71%
🏷️

Per Share Metrics

EPS (Diluted) $22.95
EPS (Basic) $23.00
Dividends / Share $6.23
Book Value / Share $29.76
EPS YoY Growth 95.99%
🏛️

Balance Sheet (FY 2025)

Total Assets $112.48B
Total Liabilities $112.48B
Stockholders' Equity $26.54B
Current Assets $55.63B
Current Liabilities $35.23B